|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2010-5-24
|
|
pubmed:abstractText |
Two aldosterone inhibitors are currently licensed for heart failure (HF) in the UK: spironolactone and eplerenone. Recent clinical guidelines recommend eplerenone after an acute myocardial infarction (MI) for patients with symptoms and/or signs of HF and left ventricular dysfunction.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1366-5278
|
|
pubmed:author |
pubmed-author:BakhaiAA,
pubmed-author:BurchJJ,
pubmed-author:FenwickLL,
pubmed-author:HarderAA,
pubmed-author:LorgellyPP,
pubmed-author:McKennaCC,
pubmed-author:PalmerSS,
pubmed-author:SuekarranSS,
pubmed-author:WalkerSS,
pubmed-author:WitteKK,
pubmed-author:WoolacottNN,
pubmed-author:WrightKK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1-162
|
|
pubmed:meshHeading |
pubmed-meshheading:20492762-Aldosterone Antagonists,
pubmed-meshheading:20492762-Bayes Theorem,
pubmed-meshheading:20492762-Clinical Trials as Topic,
pubmed-meshheading:20492762-Cost-Benefit Analysis,
pubmed-meshheading:20492762-Great Britain,
pubmed-meshheading:20492762-Heart Failure,
pubmed-meshheading:20492762-Humans,
pubmed-meshheading:20492762-Myocardial Infarction,
pubmed-meshheading:20492762-Quality-Adjusted Life Years,
pubmed-meshheading:20492762-Spironolactone,
pubmed-meshheading:20492762-State Medicine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
|
|
pubmed:affiliation |
Centre for Health Economics, University of York, York, UK.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Review
|
